Fig. 1 · Structure

Documents & Downloads

Galanthamine

Cat. No. A12483 CAS 357-70-0

AChE inhibitor

Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
AChE  

Cellular Effect

Cell Line Activity Value Description Reference
BJ IC50 > 50 μM Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay [PMID: 22921081]
CCRF-CEM IC50 > 50 μM Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay [PMID: 22921081]
Cortical neurone EC50 1.48 μM Neuroprotective activity against NMDA-induced excitotoxicity in Sprague-Dawley rat primary cortical neurons assessed as increase in cell viability after 3 hrs by MTT assay [PMID: 27376495]
G-361 IC50 > 50 μM Cytotoxicity against human G361 cells after 72 hrs by Calcein AM assay [PMID: 22921081]
HeLa IC50 > 50 μM Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay [PMID: 22921081]
K562 IC50 > 50 μM Cytotoxicity against human K562 cells after 72 hrs by Calcein AM assay [PMID: 22921081]
MCF7 IC50 > 50 μM Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay [PMID: 22921081]
SH-SY5Y EC50 1.94 μM Neuroprotective activity against okadaic acid-induced tau phosphorylation-mediated cell death in human SH-SY5Y cells assessed as increase in cell viability after 24 hrs by XTT assay [PMID: 27376495]
SH-SY5Y EC50 2.81 μM Neuroprotective activity against oligomycine/rotenone-induced oxidative stress-mediated cell death in human SH-SY5Y cells assessed as increase in cell viability after 24 hrs by XTT assay [PMID: 27376495]
SH-SY5Y IC50 747 nM Neuroprotective activity in human SH-SY5Y cells assessed as protection against NMDA-induced cell death after 6 hrs by MTS assay [PMID: 23033965]

10 records · Scroll to view more

Galanthamine Research Summary

This section summarizes 4 in vivo studies of Galanthamine from 3 published references. In vivo models include male Wistar rats.

Galanthamine In Vivo Studies

Intraperitoneal Galanthamine treatment reduced deposited SAA in FMF-KI mice compared with PBS-treated controls. In male Wistar rats, Galanthamine pretreatment significantly increased Ki67+IR in both AIE and CON groups relative to vehicle-treated rats. In LPS-exposed male Kunming mice treated with Galanthamine, escape latency during training was significantly decreased in the LPS + galantamine group compared with the LPS group. In α7nAChR deficient FMF-KI mice, Galanthamine treatment resulted in significantly smaller spleens compared with PBS-treated controls. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced SAA deposition in FMF-KI mice

Animal study · FMF-KI mice; treated animals (n = 2) compared with controls (n = 3) [1]

FMF-KI mice received intraperitoneal Galanthamine at an escalated dose of 4–12 mg/kg. Treated animals showed ~ 50% reduction in deposited SAA compared with PBS-treated controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SAA deposition; Band density was quantified with ImageJ and normalized by actinkidney SAA deposition escalated dose (4–12 mg/kg), twice daily for 8 weeks: ~ 50% reduction in deposited SAA[1]

Conditions shared by the study groups

Route
intraperitoneally (i.p.)
Treatment course
twice daily for 8 weeks
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Galanthamine 4–12 mg/kgPBS-treated (Ct) FMF-KI mice~ 50% reduction in deposited SAA in treated animals (n = 2) compared with controls (n = 3)[1]
Galanthamine 4–12 mg/kg
Model: FMF-KI mice; treated animals (n = 2) compared with controls (n = 3)
Methods and source locations

Compound reported in the paper: Galanthamine; Compound label in the paper: Galantamine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animal experiments (S7, S8); Results > Galantamine lowers markers of chronic inflammation (S74, S76, S80, S81)

SAA deposition; Band density was quantified with ImageJ and normalized by actin: SAA deposition; Band density was quantified with ImageJ and normalized by actin; comparator: PBS-treated (Ct) FMF-KI mice — Materials and methods > Animal experiments (S8); Results > Galantamine lowers markers of chronic inflammation (S74, S76, S80, S81)

Galanthamine 4–12 mg/kg · Materials and methods > Animal experiments (S8); Results > Galantamine lowers markers of chronic inflammation (S74, S76)

Ki67+IR Following Pretreatment in Male Wistar Rats

Animal study · male Wistar rats [2]

Male Wistar rats received Galanthamine by intraperitoneal injection before ethanol or water gavage. Pretreatment significantly increased Ki67+IR in both AIE and CON groups relative to vehicle-treated rats.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ki67+IRKi67+IR 173.1%[2]

Conditions shared by the study groups

Route
intraperitoneal injection (i.p.)
Treatment course
30 min prior to either ethanol or water gavage on every gavage treatment day of the AIE paradigm; 16 doses across 30 days; Treatment ended on P54; until P70
Vehicle
saline (vehicle)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Galanthamine 4 mg/kgCON-Vehgalantamine pretreatment significantly increased Ki67+IR in both AIE and CON groups relative to vehicle-treated rats; CON-Gal; 173.1%; relative to CON-Veh[2]
Galanthamine 4 mg/kg
Model: male Wistar rats
Methods and source locations

Compound reported in the paper: Galanthamine; Compound label in the paper: Galantamine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S10, S12, S13); Materials and methods > Galantamine treatment and euthanasia (S29, S30); Results > Study 1 (prevention): mechanisms of AIE-reduced adult neurogenesis and galantamine prevention (S111, S127); Table 6 (T6.h1, T6.r1)

Ki67+IR: Ki67+IR; comparator: CON-Veh — Results > Study 1 (prevention): mechanisms of AIE-reduced adult neurogenesis and galantamine prevention (S111, S127); Table 6 (T6.h1, T6.r1)

Galanthamine 4 mg/kg · Materials and methods > Animals (S12, S13); Materials and methods > Galantamine treatment and euthanasia (S29, S30); Results > Study 1 (prevention): mechanisms of AIE-reduced adult neurogenesis and galantamine prevention (S111, S127); Table 6 (T6.h1, T6.r1)

Escape Latency in LPS-Exposed Mice

Animal study · Male Kunming mice; LPS-exposed mice; 10 mice per group [3]

LPS-exposed male Kunming mice received Galanthamine by intraperitoneal injection beginning before LPS injection. Escape latency during training was significantly decreased in the LPS + galantamine group compared with the LPS group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
escape latency during training days 2–4Reported result the escape latency during training days 2–4 was significantly decreased in the LPS + galantamine group compared to the LPS group (all P < 0.05)[3]

Conditions shared by the study groups

Route
ip injection
Treatment course
for 14 days starting 1 day before the LPS injection
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Galanthamine 4 mg/kgthe LPS group—vehicle treatment and ICV injection of LPSthe escape latency during training days 2–4 was significantly decreased in the LPS + galantamine group compared to the LPS group (all P < 0.05)[3]
Galanthamine 4 mg/kg
Model: Male Kunming mice; LPS-exposed mice; 10 mice per group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Galanthamine; Compound label in the paper: Galantamine

Evidence for Galanthamine as the hydrobromide form reported in the paper, not the free base/neutral form supplied as A12483; no salt equivalence, dose conversion or lot validation.

Methods > Animals (S1); Methods > Experimental protocol (S5, S6, S7, S9, S11); Results > Galantamine improves cognition in LPS-exposed mice (S81, S82)

escape latency during training days 2–4: escape latency during training days 2–4; comparator: the LPS group—vehicle treatment and ICV injection of LPS — Results > Galantamine improves cognition in LPS-exposed mice (S82)

Galanthamine 4 mg/kg · Methods > Experimental protocol (S7); Results > Galantamine improves cognition in LPS-exposed mice (S82)

Spleen Size in α7nAChR Deficient FMF-KI Mice

Animal study · α7nAChR deficient FMF-KI mice; treated n = 5; control n = 4 [1]

α7nAChR deficient FMF-KI mice received Galanthamine intraperitoneally. Treated mice had significantly smaller spleens compared with PBS-treated controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Spleen sizes (mg)Reported result After 4 weeks of treatment with galantamine, α7nAChR deficient FMF-KI mice had significantly smaller spleens compared with PBS-treated controls[1]

Conditions shared by the study groups

Route
intraperitoneally (i.p.)
Treatment course
4–6 weeks of treatment with galantamine (escalated to 12 mg/kg twice daily) starting at age ~ 4–5 weeks
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Galanthamine escalated to 12 mg/kgPBS-treated controlsAfter 4 weeks of treatment with galantamine, α7nAChR deficient FMF-KI mice had significantly smaller spleens compared with PBS-treated controls[1]
Galanthamine escalated to 12 mg/kg
Model: α7nAChR deficient FMF-KI mice; treated n = 5; control n = 4
Methods and source locations

Compound reported in the paper: Galanthamine; Compound label in the paper: Galantamine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animal experiments (S7, S8); Results > Galantamine controls splenomegaly in vagotomized and α7nAChR knockout (α7-KO) FMF-KI mice (S93, S99)

Spleen sizes (mg): Spleen sizes (mg); comparator: PBS-treated controls — Results > Galantamine controls splenomegaly in vagotomized and α7nAChR knockout (α7-KO) FMF-KI mice (S93, S99)

Galanthamine escalated to 12 mg/kg · Materials and methods > Animal experiments (S8); Results > Galantamine controls splenomegaly in vagotomized and α7nAChR knockout (α7-KO) FMF-KI mice (S93, S99)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 357-70-0
Applications AChE inhibitor
Formula C17H21NO3
Molecular Weight 287.35
Synonyms Galantamine
SMILES
O[C@@H]1C[C@@H]2OC3=C4C(CN(C)CC[C@]42C=C1)=CC=C3OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 99 mg/mL (344.52 mM)
Water 56 mg/mL (194.88 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Galanthamine Research References

  1. [1] Mughrabi IT, Ochani M, Tanovic M, et al. Galantamine attenuates autoinflammation in a mouse model of familial mediterranean fever. Mol Med (2022). PMID: 36494621 DOI: 10.1186/s10020-022-00571-9 Source material
  2. [2] Macht V, Vetreno R, Elchert N, et al. Galantamine prevents and reverses neuroimmune induction and loss of adult hippocampal neurogenesis following adolescent alcohol exposure. J Neuroinflammation (2021). PMID: 34530858 DOI: 10.1186/s12974-021-02243-7 Source material
  3. [3] Liu Y, Zhang Y, Zheng X, et al. Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice. J Neuroinflammation (2018). PMID: 29669582 DOI: 10.1186/s12974-018-1141-5 Source material

Added to your cart

View Cart Checkout
Loading...